ID: ALA332700

Max Phase: Preclinical

Molecular Formula: C17H27N3S

Molecular Weight: 305.49

Molecule Type: Small molecule

Associated Items:

Representations

Canonical SMILES:  CCCCCCSc1nccnc1C1CN2CCC1CC2

Standard InChI:  InChI=1S/C17H27N3S/c1-2-3-4-5-12-21-17-16(18-8-9-19-17)15-13-20-10-6-14(15)7-11-20/h8-9,14-15H,2-7,10-13H2,1H3

Standard InChI Key:  SKDLQXRLZCZVIX-UHFFFAOYSA-N

Associated Targets(non-human)

Muscarinic acetylcholine receptor 3770 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Mus musculus 284745 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Mustela putorius furo 1007 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Muscarinic acetylcholine receptor M1 3437 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

A9 98 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 305.49Molecular Weight (Monoisotopic): 305.1926AlogP: 3.96#Rotatable Bonds: 7
Polar Surface Area: 29.02Molecular Species: NEUTRALHBA: 4HBD: 0
#RO5 Violations: 0HBA (Lipinski): 3HBD (Lipinski): 0#RO5 Violations (Lipinski): 0
CX Acidic pKa: CX Basic pKa: 7.74CX LogP: 3.46CX LogD: 2.96
Aromatic Rings: 1Heavy Atoms: 21QED Weighted: 0.56Np Likeness Score: -0.22

References

1. Ward JS, Merritt L, Calligaro DO, Bymaster FP, Shannon HE, Sawyer BD, Mitch CH, Deeter JB, Peters SC, Sheardown MJ, Olesen PH, Swedberg MD, Sauerberg P..  (1995)  Functionally selective M1 muscarinic agonists. 3. Side chains and azacycles contributing to functional muscarinic selectivity among pyrazinylazacycles.,  38  (18): [PMID:7658434] [10.1021/jm00018a007]
2. Mitch CH, Brown TJ, Bymaster FP, Calligaro DO, Dieckman D, Merrit L, Peters SC, Quimby SJ, Shannon HE, Shipley LA, Ward JS, Hansen K, Olesen PH, Sauerberg P, Sheardown MJ, Swedberg MD, Suzdak P, Greenwood B..  (1997)  Muscarinic analgesics with potent and selective effects on the gastrointestinal tract: potential application for the treatment of irritable bowel syndrome.,  40  (4): [PMID:9046345] [10.1021/jm9602470]

Source